Stent placement cost neutral vs PTCA for US Medicare

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.438, 2003-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adverse events cost US Medicare, hospitals dearly

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 518, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

The lowest-cost COX-2 inhibitor available through the US Medicare drug discount card programme is Merck's rofecoxib [Vioxx]

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 453, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

US Medicare - the debate hots up

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 265, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Etanercept or infliximab: costs to US Medicare

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 276, 2000-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Etanercept or infliximab: costs to US Medicare

By  

Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite